Jun-Hua Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jun-Hua Zheng has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Huan Liu
Tongji University
2 shared publicationsTian-Bao Huang
Department of Urology, Shanghai Tenth People's Hospital, Tongji University, 301 Yanchang Road, Shanghai, 200072, China
2 shared publicationsZhui-Feng Guo
Tongji University
2 shared publicationsJiang Geng
Tongji University
1 shared publication- Jiang Geng
Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
1 shared publication Xiao-Long Zhang
Tongji University
1 shared publication
Latest Publications
- 1 April 2014
- Published by Springer Nature in International Urology and Nephrology
- Vol. 46 (9) , 1715-1728
Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies
Several epidemiologic studies were performed to clarify the protective effect of regular aspirin use on prostate cancer risk; however, the results remain controversial. Therefore, we conducted this meta-analysis to assess the association between regular aspirin use and risk of prostate cancer.
- 1 April 2014
- Published by Springer Nature in International Urology and Nephrology
- Vol. 46 (9) , 1715-1728
Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies
Several epidemiologic studies were performed to clarify the protective effect of regular aspirin use on prostate cancer risk; however, the results remain controversial. Therefore, we conducted this meta-analysis to assess the association between regular aspirin use and risk of prostate cancer.
- 28 March 2014
- Published by Springer Nature in International Urology and Nephrology
- Vol. 46 (8) , 1481-1493
Coffee consumption and urologic cancer risk: a meta-analysis of cohort studies
Controversial results were reported among several epidemiologic studies on the relationship between coffee consumption and urologic cancer risk. We, therefore, conducted this meta-analysis to clarify these associations. Electronic databases including Pubmed, Embase and Cochrane library were searched between January 1966 and August 2013 for eligible studies. Pooled relative risk (RR) and its 95 % confidence interval (CI) were calculated. All P values are two tailed. Thirteen cohorts were eligible for inclusion. As to prostate cancer (PCa), significant reverse association was found among highest versus none/lowest analysis with acceptable heterogeneity (RR 0.86, 95 % CI 0.79–0.95; I 2 25 %, P value for heterogeneity: 0.221). A pooled RR which assessed advanced PCa was 0.73 (with 95 % CI 0.50–1.07), and a slight stronger reverse association was found in fatal PCa. However, a slight insignificant reverse association, basing on 8 studies with 9 outcomes, was found in dose–response analysis (RR 0.98, 95 % CI 0.93–1.03). For kidney and bladder cancer, insignificant associations were found in both highest versus none/lowest analyses and dose–response analyses. Our findings suggest that coffee consumption may reduce the risk of PCa. No associations were found with both bladder and kidney cancer. Further well-designed large-scaled cohort studies are warranted to provide more definitive conclusions.
- 28 March 2014
- Published by Springer Nature in International Urology and Nephrology
- Vol. 46 (8) , 1481-1493
Coffee consumption and urologic cancer risk: a meta-analysis of cohort studies
Controversial results were reported among several epidemiologic studies on the relationship between coffee consumption and urologic cancer risk. We, therefore, conducted this meta-analysis to clarify these associations. Electronic databases including Pubmed, Embase and Cochrane library were searched between January 1966 and August 2013 for eligible studies. Pooled relative risk (RR) and its 95 % confidence interval (CI) were calculated. All P values are two tailed. Thirteen cohorts were eligible for inclusion. As to prostate cancer (PCa), significant reverse association was found among highest versus none/lowest analysis with acceptable heterogeneity (RR 0.86, 95 % CI 0.79–0.95; I 2 25 %, P value for heterogeneity: 0.221). A pooled RR which assessed advanced PCa was 0.73 (with 95 % CI 0.50–1.07), and a slight stronger reverse association was found in fatal PCa. However, a slight insignificant reverse association, basing on 8 studies with 9 outcomes, was found in dose–response analysis (RR 0.98, 95 % CI 0.93–1.03). For kidney and bladder cancer, insignificant associations were found in both highest versus none/lowest analyses and dose–response analyses. Our findings suggest that coffee consumption may reduce the risk of PCa. No associations were found with both bladder and kidney cancer. Further well-designed large-scaled cohort studies are warranted to provide more definitive conclusions.